Multiple Myeloma is a malignant proliferation of monoclonal plasma cells that are derived from post-germinal-center B cells. Myeloma cells produce monoclonal paraproteins and cause lytic bone lesions, anemia and renal failure. Myeloma accounts for almost 14% of all hematologic cancers. Despite intensive study, the etiology of Multiple Myeloma is unknown. Reports of substantial familial clustering of myeloma cases have been reported, including by our own team. These data are consistent with the existence of specific risk genes that predispose to Familial Myeloma and associated malignancies. Analogous to the BRCA1 breast cancer constitutional risk gene, which affects treatment decisions (surgical management and PARP inhibitors), surveillance (annual breast MRI) and prevention (oophorectomy), identification of Familial Myeloma risk genes is likely to provide important new mechanistic insights that can also significantly impact important clinical decision making for both affected individuals and at-risk family members. Unfortunately, there are currently no known constitutional familial or sporadic myeloma risk genes. Here, we will use an innovative strategy incorporating previously untapped computational resources to discover and rigorously validate novel constitutional cancer risk genes in one of the largest Familial Myeloma clinical and genetic resources in the world. We will use an innovative tiered whole exome and full genome sequencing strategy of well- characterized Familial Myeloma probands and available biospecimens to help discover, prioritize and validate causative constitutional mutation candidates. Our overall goal is to discover and validate the first constitutional Familial Myeloma risk genes in clinically well- characterized kindreds. This is anticipated to increase the number of patients and their at-risk family members who can benefit from increased cancer surveillance, early detection and cancer prevention.
Despite intensive study, the etiology of Multiple Myeloma is unknown. Here, we will use an innovative strategy incorporating previously untapped computational resources to discover and rigorously validate novel constitutional cancer risk genes in one of the largest Familial Myeloma clinical and genetic resources in the world. Our overall goal is to discover and validate the first constitutional Familial Myeloma risk genes in clinically well-characterized kindreds.
|Chen, Siwei; Fragoza, Robert; Klei, Lambertus et al. (2018) An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders. Nat Genet 50:1032-1040|
|Wei, Xiaomu; Calvo-Vidal, M Nieves; Chen, Siwei et al. (2018) Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 78:2747-2759|
|Meyer, Michael J; Beltrán, Juan Felipe; Liang, Siqi et al. (2018) Interactome INSIDER: a structural interactome browser for genomic studies. Nat Methods 15:107-114|
|Waller, Rosalie G; Darlington, Todd M; Wei, Xiaomu et al. (2018) Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet 14:e1007111|
|Liang, Siqi; Tippens, Nathaniel D; Zhou, Yaoda et al. (2017) iRegNet3D: three-dimensional integrated regulatory network for the genomic analysis of coding and non-coding disease mutations. Genome Biol 18:10|
|Guo, Yu; Alexander, Katherine; Clark, Andrew G et al. (2016) Integrated network analysis reveals distinct regulatory roles of transcription factors and microRNAs. RNA 22:1663-1672|
|Pu, Mintie; Ni, Zhuoyu; Wang, Minghui et al. (2015) Trimethylation of Lys36 on H3 restricts gene expression change during aging and impacts life span. Genes Dev 29:718-31|
|Das, Jishnu; Gayvert, Kaitlyn M; Bunea, Florentina et al. (2015) ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers. BMC Genomics 16:263|
|Bastos de Oliveira, Francisco Meirelles; Kim, Dongsung; Cussiol, José Renato et al. (2015) Phosphoproteomics reveals distinct modes of Mec1/ATR signaling during DNA replication. Mol Cell 57:1124-1132|
|Wei, Xiaomu; Das, Jishnu; Fragoza, Robert et al. (2014) A massively parallel pipeline to clone DNA variants and examine molecular phenotypes of human disease mutations. PLoS Genet 10:e1004819|
Showing the most recent 10 out of 23 publications